Predictors of Patient-reported Fatigue Symptom Severity in a Nationwide Multiple Sclerosis Cohort
Overview
Authors
Affiliations
Background: Fatigue is a debilitating symptom of multiple sclerosis (MS), but its relation to sociodemographic and disease-related characteristics has not been investigated in larger studies. The objectives of this study were to evaluate predictors of self-reported fatigue in a Swedish nationwide register-based MS cohort.
Methods: Using a repeated cross-sectional design, we included 2,165 persons with relapsing- remitting and secondary progressive MS with one or multiple Fatigue Scale for Motor and Cognitive Functions (FSMC) scores, which was modelled using multivariable linear regressions for multiple predictors.
Results: Only associations to expanded disability status scale (EDSS) and Symbol Digit Modalities Test (SDMT) were considered clinically meaningful among MS-associated characteristics in our main model; compared to mild disability (EDSS 0-2.5), those with severe disability (EDSS ≥6) scored 17.6 (95% CI 13.1-22.2) FSMC points higher, while the difference was 10.7 (95% CI 8.0-13.4) points for the highest and lowest quartiles of SDMT. Differences between highest and lowest quartiles of health-related quality of life (HRQoL) instruments were even greater and considered clinically meaningful; EuroQoL Visual Analogue Scale (EQ-VAS) 31.9 (95% CI 29.9-33.8), Multiple Sclerosis Impact Scale (MSIS-29) psychological component 35.6 (95% CI 33.8-37.4) and MSIS-29 physical component 45.5 (95% CI 43.7-47.4).
Conclusion: Higher self-reported fatigue is associated with higher disability level and worse cognitive processing speed, while associations to other MS-associated characteristics including MS type, line of disease modifying therapy (DMT), MS duration, relapse and new cerebral lesions are weak. Furthermore, we found a strong correlation between high fatigue rating and lower ratings on health-related quality of life instruments.
Machado A, Wredendal E, Fink K, Friberg E BMJ Open. 2025; 14(12):e087563.
PMID: 39806622 PMC: 11667484. DOI: 10.1136/bmjopen-2024-087563.
Yi X, Zhang Y, Du Q, Kang J, Song S, Li T Front Neurol. 2024; 15:1457788.
PMID: 39416662 PMC: 11479926. DOI: 10.3389/fneur.2024.1457788.
Wasem J, Heer Y, Karamasioti E, Muros-Le Rouzic E, Marcelli G, Di Maio D Pharmacoecon Open. 2024; 8(5):665-678.
PMID: 38949748 PMC: 11362420. DOI: 10.1007/s41669-024-00501-x.
Englund S, Frisell T, Qu Y, Gandhi K, Hulten A, Kierkegaard M J Neurol Neurosurg Psychiatry. 2024; 95(11):1012-1020.
PMID: 38744460 PMC: 11503085. DOI: 10.1136/jnnp-2024-333595.
Sellitto G, Ruotolo I, Ianniello A, Felicetti F, DAmbrosi G, Berardi A BMC Neurol. 2024; 24(1):138.
PMID: 38664640 PMC: 11044535. DOI: 10.1186/s12883-024-03643-x.